Relevance of tumor-infiltrating lymphocytes in breast cancer

BMC Medicine

Sherene Loi²  Phillip K. Darcy¹  Mariam Mansour³  Chenhao Zhou³  Zhi Ling Teo³  Peter Savas³  Paul A. Beavis³  Sathana Dushyanthen³ 

[1]Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia

[2]Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

[3]Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

关键词: tumor-infiltrating lymphocytes;    triple negative breast cancer;    TNBC;    TILs;    neoadjuvant chemotherapy;    NAC;    immunotherapy;    immunity;    HER2;    Breast cancer;   

Others  :  1222748
DOI  :  10.1186/s12916-015-0431-3

 received in 2015-05-11, accepted in 2015-07-22,  发布年份 2015

【 摘 要 】

While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recent studies have demonstrated evidence of significant immune cell infiltration via tumor-infiltrating lymphocytes in a subset of patient tumors. In this review we present the current evidence highlighting the clinical relevance and utility of tumor-infiltrating lymphocytes in breast cancer. Retrospective and prospective studies have shown that the presence of tumor-infiltrating lymphocytes is a prognostic marker for higher responses to neoadjuvant chemotherapy and better survival, particularly in triple negative and HER2-positive early breast cancer. Further work is required to determine the immune subsets important in this response and to discover ways of encouraging immune infiltrate in tumor-infiltrating lymphocytes-negative patients.

【 授权许可】

   
2015 Dushyanthen et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331:1565-70.
• [2]Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014; 27:16-25.
• [3]Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C et al.. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013; 19:28-33.
• [4]Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G et al.. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004; 53:1146-52.
• [5]Monjazeb AM, Zamora AE, Grossenbacher SK, Mirsoian A, Sckisel GD, Murphy WJ. Immunoediting and antigen loss: overcoming the Achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol. 2013; 3:197.
• [6]Enderling H, Hlatky L, Hahnfeldt P. Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor Biol Med Model. 2012; 9:31.
• [7]Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013; 1284:1-5.
• [8]Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011; 241:104-18.
• [9]Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3:991-8.
• [10]O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM et al.. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012; 209:1869-82.
• [11]Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012; 12:1597-611.
• [12]Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-64.
• [13]Wolchok JD, Chan TA. Cancer: antitumour immunity gets a boost. Nature. 2014; 515:496-8.
• [14]van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190:355-66.
• [15]Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014; 211:715-25.
• [16]Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL et al.. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014; 111:11774-9.
• [17]Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res. 2014; 2:970-80.
• [18]Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al.. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28:3167-75.
• [19]Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al.. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11:155-64.
• [20]Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33:1974-198.
• [21]Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C et al.. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A. 2013; 110:14711-6.
• [22]Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S et al.. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor t-cell responses. Cancer Immunol Res. 2015; 3:506-17.
• [23]Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012; 33:231-7.
• [24]Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother. 2012; 61:917-26.
• [25]Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al.. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103:13132-7.
• [26]Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014; 27:1-7.
• [27]Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X et al.. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013; 132:967-77.
• [28]Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013; 210:1389-402.
• [29]Holtzhausen A, Zhao F, Evans KS, Hanks BA. Early carcinogenesis involves the establishment of immune privilege via intrinsic and extrinsic regulation of indoleamine 2,3-dioxygenase-1: translational implications in cancer immunotherapy. Front Immunol. 2014; 5:438.
• [30]Platten M, von Knebel DN, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 2014; 5:673.
• [31]Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z et al.. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis. 2014; 5: Article ID e1563
• [32]Bedoya AM, Tate DJ, Baena A, Cordoba CM, Borrero M, Pareja R et al.. Immunosuppression in cervical cancer with special reference to arginase activity. Gynecol Oncol. 2014; 135:74-80.
• [33]Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J et al.. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013; 123:1580-9.
• [34]Ghansah T. A novel strategy for modulation of MDSC to enhance cancer immunotherapy. Oncoimmunology. 2012; 1:984-5.
• [35]Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med. 2014; 3:215-24.
• [36]Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013; 140:13-21.
• [37]Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H et al.. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012; 132:793-805.
• [38]West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13:R126.
• [39]Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al.. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013; 31:860-7.
• [40]Wimberly H, Brown JR, Schalper KA, Haack H, Silver MR, Nixon C et al.. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2014; 3:326-32.
• [41]Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R et al.. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015; 33:983-91.
• [42]Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al.. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004; 34:336-44.
• [43]Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8:59-73.
• [44]Ghiringhelli F, Apetoh L. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Expert Rev Clin Immunol. 2014; 10:19-30.
• [45]Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al.. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15:1170-8.
• [46]Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al.. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13:1050-9.
• [47]Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002; 62:2353-8.
• [48]Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H et al.. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother. 2013; 62:383-91.
• [49]Homma Y, Taniguchi K, Nakazawa M, Matsuyama R, Mori R, Takeda K et al.. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin Transl Oncol. 2014; 16:330-5.
• [50]Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander M, Nilsson B et al.. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother. 2009; 58:111-20.
• [51]Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005; 105:2862-8.
• [52]Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol. 2011; 73:301-8.
• [53]Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D et al.. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001; 61:3689-97.
• [54]Park JY, Jang MJ, Chung YH, Kim KY, Kim SS, Lee WB et al.. Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. Int Immunopharmacol. 2009; 9:1530-9.
• [55]Hannesdottir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N et al.. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013; 43:2718-29.
• [56]Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al.. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003; 170:4905-13.
• [57]Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31:51-72.
• [58]Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N et al.. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997; 3:817-9.
• [59]Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al.. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28:105-13.
• [60]Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B et al.. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008; 14:2413-20.
• [61]Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F et al.. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012; 30:1996-2004.
• [62]Yu H, Yang J, Jiao S, Li Y, Zhang W, Wang J. T-box transcription factor 21 expression in breast cancer and its relationship with prognosis. Int J Clin Exp Pathol. 2014; 7:6906-13.
• [63]Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I et al.. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013; 8: Article ID e79775
• [64]Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V et al.. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014; 25:611-8.
• [65]Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D et al.. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25:1544-50.
• [66]Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN et al.. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32:2959-66.
• [67]Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al.. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004; 10:5650-5.
• [68]Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C et al.. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol. 2015; 1:448-54.
• [69]Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al.. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94:259-67.
• [70]Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014; 15:e58-68.
• [71]Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M et al.. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012; 136:107-16.
• [72]Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE et al.. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013; 109:2705-13.
• [73]Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013; 16:32-9.
• [74]Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014; 20:5995-6005.
• [75]Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee A et al.. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29:1949-55.
• [76]West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH et al.. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013; 108:155-62.
• [77]Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S et al.. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009; 22:273-8.
• [78]Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C et al.. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011; 224:389-400.
• [79]Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R et al.. Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat. 2012; 135:459-67.
• [80]Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012; 109:2796-801.
• [81]Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A et al.. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013; 123:2873-92.
• [82]Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E et al.. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012; 189:5029-36.
• [83]Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother. 2007; 56:1285-97.
• [84]Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al.. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007; 56:469-76.
• [85]Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2012; 62:153-9.
• [86]Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA et al.. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013; 11:16.
• [87]Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC et al.. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001; 7:3025-30.
• [88]Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al.. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005; 201:1591-602.
• [89]Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al.. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013; 210:1695-710.
• [90]DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF et al.. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1:54-67.
• [91]Alistar A, Chou J, Nagalla S, Black M, DAgostino R, Miller L. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med. 2014; 6:80.
• [92]Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L et al.. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014; 20:2773-82.
• [93]Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA et al.. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146:15-24.
• [94]Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013; 139:667-76.
• [95]Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O et al.. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014; 63:395-406.
• [96]Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH et al.. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20:5064.
• [97]Rahbar R, Lin A, Ghazarian M, Yau HL, Paramathas S, Lang PA et al.. B7-h4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. Cancer Immunol Res. 2015; 3:184-95.
• [98]Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H et al.. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003; 18:849-61.
• [99]Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003; 100:10388-92.
• [100]Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med. 2014; 12:36.
• [101]Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM et al.. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013; 8: Article ID e61895
• [102]Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM et al.. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012; 72:3163-74.
• [103]Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E et al.. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520:373-7.
• [104]Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T et al.. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015; 21:1639.
• [105]Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S et al.. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014; 2:70-9.
• [106]Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z et al.. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol. 2004; 173:3002-12.
• [107]Gray JC, French RR, James S, Al-Shamkhani A, Johnson PW, Glennie MJ. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol. 2008; 38:2499-511.
• [108]Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S et al.. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013; 19:6151-62.
• [109]Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P et al.. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer. 2005; 116:934-43.
• [110]Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al.. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446:153-8.
• [111]Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP et al.. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44:1006-14.
• [112]Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al.. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318:1108-13.
• [113]Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 2012; 72:581-91.
• [114]Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF et al.. Randomized selection design trial evaluating CD8+−enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013; 31:2152-9.
• [115]Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S et al.. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013; 8: Article ID e60031
• [116]Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol. 2012; 189:5147-54.
• [117]Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J et al.. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012; 18:6758-70.
• [118]Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013; 13:525-41.
• [119]Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al.. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371:1507-17.
• [120]Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC et al.. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72:3928-37.
• [121]John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM et al.. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013; 19:5636-46.
• [122]Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C et al.. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015; 33:1688.
• [123]Ishikawa T, Adachi S, Okayama T, Kokura S, Mizushima K, Doi T et al.. Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with naive rather than differentiated T cells. Oncol Rep. 2015; 33:2545.
• [124]Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al.. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015; 26:259-71.
• [125]Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al.. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384:164-72.
• [126]Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY et al.. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007; 67:7477-86.
• [127]Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E et al.. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010; 18:1947-59.
• [128]Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11:6713-21.
• [129]Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F et al.. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011; 71:768-78.
• [130]Xu W, Cai J, Li S, Zhang H, Han J, Wen M et al.. Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment. Scand J Immunol. 2013; 78:50-60.
• [131]Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother. 2012; 61:275-82.
• [132]Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L et al.. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol. 2008; 129:219-29.
• [133]Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H et al.. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013; 38:729-41.
• [134]Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B et al.. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014; 74:104-18.
• [135]Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al.. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010; 29:482-91.
• [136]Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW et al.. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 2013; 73:2493-504.
• [137]Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y et al.. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006; 66:1105-13.
• [138]Mikyskova R, Indrova M, Vlkova V, Bieblova J, Simova J, Parackova Z, et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. 2014; in press.
• [139]Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 2008; 26:1024-31.
• [140]Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012; 14:R48.
• [141]Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K et al.. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012; 43:1688-94.
• [142]Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M et al.. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25:1536-43.
• [143]Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J et al.. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014; 25:1570-7.